Voyager Therapeutics Taps Nathan Jorgensen of Vor Bio as CFO, Effective July 8

6/13/24 7:20:10 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $VYGR alert in real time by email

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.

Get the next $VYGR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VYGR

Date	Price Target	Rating	Analyst
10/16/2024	$15.00	Outperform	Leerink Partners
3/26/2024	$22.00	Buy	Guggenheim
3/19/2024	$30.00	Buy	H.C. Wainwright
3/7/2024	$16.00	Buy	Citigroup
1/2/2024	$14.00	Equal Weight → Overweight	Wells Fargo
5/10/2023	$18.00	Buy	Truist
3/10/2023	$14.00	Outperform	Oppenheimer
11/3/2021	$5.50 → $4.00	Neutral	Chardan Capital

More analyst ratings

$VYGR
Press Releases

Fastest customizable press release news feed in the world

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager's IV-delivered, CNS-penetrant TRACER capsids - LEXINGTON, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has selected a lead development candidate, VY1706, for its tau silencing gene therapy program in Alzheimer's disease. The Company anticipates filing an investigational new drug (IND) application with the U.S. Food and Drug Administratio
11/20/24 7:00:00 AM ET
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Voyager Reports Third Quarter 2024 Financial and Operating Results
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target tau in Alzheimer's - - Continued partnership progress in Q3 2024 evidenced by new capsid license and new gene therapy development candidate selection - - INDs on track for three CNS gene therapies in 2025 in SOD1 ALS, GBA1 Parkinson's and other GBA1-mediated disease, and Friedreich's ataxia programs - LEXINGTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Thera
11/12/24 4:01:00 PM ET
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences: Truist Securities BioPharma Symposium, in New York City, including a panel discussion on Genetic Medicines at 1:45 p.m. ET on November 7, 2024Guggenheim Inaugural Healthcare Innovation Conference*, in Boston, including a fireside chat at 2:00 p.m. ET on November 13, 2024B. Riley Securities' Next-Gen Tissue Delivery Modalities Virtual Summit, virtual, including a fireside chat at 1:30 p.m. ET on November 14, 2024Stifel 2024 Healthcare C
11/6/24 7:00:00 AM ET
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Voyager Reports Third Quarter 2024 Financial and Operating Results
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target tau in Alzheimer's - - Continued partnership progress in Q3 2024 evidenced by new capsid license and new gene therapy development candidate selection - - INDs on track for three CNS gene therapies in 2025 in SOD1 ALS, GBA1 Parkinson's and other GBA1-mediated disease, and Friedreich's ataxia programs - LEXINGTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Thera
11/12/24 4:01:00 PM ET
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.
11/5/24 7:00:00 AM ET
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease - - Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND meeting for SOD1 ALS development candidate - - Appointed strategic financial leader Nathan Jorgensen, Ph.D., as Chief Financial Officer - - Strong cash position of $371 million as of June 30, 2024, expected to provide runway through multiple clinical data readouts into 2027 - LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology comp
8/6/24 4:01:00 PM ET
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe
6/13/24 7:00:00 AM ET
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
NorthStar Appoints Peter Pfreundschuh to Board of Managers
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business
4/15/24 9:00:00 AM ET
$FREQ
$URGN
$VYGR
$IMMU
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. "Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through
3/13/24 7:00:00 AM ET
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Voyager Therapeutics Taps Nathan Jorgensen of Vor Bio as CFO, Effective July 8

Chat with this insight

Recent Analyst Ratings for $VYGR

$VYGR Press Releases

Fastest customizable press release news feed in the world

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease

Voyager Reports Third Quarter 2024 Financial and Operating Results

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

$VYGR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

$VYGR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners initiated coverage on Voyager Therapeutics with a new price target

Guggenheim initiated coverage on Voyager Therapeutics with a new price target

H.C. Wainwright initiated coverage on Voyager Therapeutics with a new price target

$VYGR SEC Filings

SEC Form 10-Q filed by Voyager Therapeutics Inc.

Voyager Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Voyager Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

$VYGR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Legal Officer Fahey Sandell Jacquelyn sold $34,914 worth of shares (5,999 units at $5.82), decreasing direct ownership by 7% to 86,001 units (SEC Form 4)

Chief Financial Officer Jorgensen Nathan D. was granted 80,000 shares (SEC Form 4)

SEC Form 4 filed by Chief Financial Officer Jorgensen Nathan D.

$VYGR Financials

Live finance-specific insights

$VYGR Leadership Updates

Live Leadership Updates

$VYGR Market Insights

Live Market Insights

Voyager Reports Third Quarter 2024 Financial and Operating Results

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

NorthStar Appoints Peter Pfreundschuh to Board of Managers

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer